Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy
- PMID: 28463397
- DOI: 10.1002/ijc.30755
Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy
Abstract
We aimed to retrospectively assess treatments/outcomes, including the value of high-dose-chemotherapy and autologous-stem-cell-rescue (HDC + AuSCR) and re-irradiation, in a large, European patient-cohort with relapsed intracranial germ-cell-tumors (GCTs) receiving uniform first-line therapy, including radiotherapy as standard-of-care. Fifty-eight UK/German patients (48 male/10 female) with relapsed intracranial-GCTs [13 germinoma/45 non-germinomatous GCT (NGGCT)] treated 1996-2010 as per the SIOP-CNS-GCT-96 protocol were evaluated. For germinoma, six patients relapsed with germinoma and five with NGGCT (one palliative, one teratoma patient excluded). Five-year overall-survival (OS) for the whole-group (n = 11) was 55%. Four of six germinoma relapses and two of five relapsing with NGGCT were salvaged; patients were salvaged with either standard-dose-chemotherapy (SDC) and re-irradiation or HDC + AuSCR with/without re-irradiation. Of 45 relapsed NGGCT patients, 13 were excluded (three non-protocol adherence, five teratoma, five palliation). Five-year OS for the remaining 32 relapsed malignant NGGCT patients treated with curative intent was 9% (95%CI: 2-26%). By treatment received, 5-year OS for the 10 patients receiving SDC and 22 patients treated with intention for HDC + AuSCR was 0% (0-0%) and 14% (3-36%), respectively. The three relapsed NGGCT survivors had raised HCG markers alone; two received additional irradiation. Patients with relapsed germinoma had better 5-year OS than those with relapsed NGGCT (55 vs. 9%; p = 0.007). Patients with relapsed germinoma were salvaged both with SDC and re-irradiation or HDC + AuSCR with/without re-irradiation; both represent valid treatment options. Outcomes for malignant relapse following initial diagnosis of NGGCT were exceptionally poor; the few survivors received thiotepa-based HDC + AuSCR, which is a treatment option at first malignant relapse for such patients, with further surgery/irradiation where feasible.
Keywords: germ cell tumor; high-dose chemotherapy; intracranial; non-germinoma; re-irradiation; relapse.
© 2017 UICC.
Similar articles
-
Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial.Neuro Oncol. 2017 Nov 29;19(12):1661-1672. doi: 10.1093/neuonc/nox122. Neuro Oncol. 2017. PMID: 29048505 Free PMC article.
-
Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.J Neurosurg Pediatr. 2019 Mar 1;23(3):317-324. doi: 10.3171/2018.9.PEDS18181. Epub 2018 Nov 23. J Neurosurg Pediatr. 2019. PMID: 30497152
-
Relapsing intracranial germ cell tumours warrant retreatment.Eur J Cancer. 2020 Sep;136:186-194. doi: 10.1016/j.ejca.2020.06.012. Epub 2020 Jul 22. Eur J Cancer. 2020. PMID: 32711377
-
Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome.Pediatr Blood Cancer. 2022 Oct;69(10):e29830. doi: 10.1002/pbc.29830. Epub 2022 Jun 10. Pediatr Blood Cancer. 2022. PMID: 35686831 Review.
-
Prognostic factors and therapeutic problems of primary intracranial choriocarcinoma/germ-cell tumors with high levels of HCG.J Neurooncol. 2004 Jan;66(1-2):225-40. doi: 10.1023/b:neon.0000013499.74404.81. J Neurooncol. 2004. PMID: 15015791 Review.
Cited by
-
Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial.Neuro Oncol. 2017 Nov 29;19(12):1661-1672. doi: 10.1093/neuonc/nox122. Neuro Oncol. 2017. PMID: 29048505 Free PMC article.
-
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults.Neuro Oncol. 2022 Apr 1;24(4):516-527. doi: 10.1093/neuonc/noab252. Neuro Oncol. 2022. PMID: 34724065 Free PMC article.
-
A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors.Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):143-151. doi: 10.1016/j.ijrobp.2021.12.166. Epub 2022 Jan 4. Int J Radiat Oncol Biol Phys. 2022. PMID: 34990779 Free PMC article. Clinical Trial.
-
CNS Germ Cell Tumors: Molecular Advances, Significance in Risk Stratification and Future Directions.Brain Sci. 2024 Apr 29;14(5):445. doi: 10.3390/brainsci14050445. Brain Sci. 2024. PMID: 38790424 Free PMC article. Review.
-
CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past.Neuro Oncol. 2022 Nov 2;24(11):1962-1963. doi: 10.1093/neuonc/noac119. Neuro Oncol. 2022. PMID: 35512703 Free PMC article. No abstract available.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical